To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.

Association for Multiple Endocrine Neoplasia Disorders (AMEND)


The Warehouse
No. 1 Draper Street
Kent, TN4 0PG United Kingdom





Email Address

[email protected]


The Association for Multiple Endocrine Neoplasia Disorders (AMEND), a non-profit UK registered charity since 2002, is a patient support group run by volunteers for the benefit of everyone affected by the multiple endocrine neoplasia disorders and their associated endocrine growths. In addition to providing worldwide email and telephone support, AMEND runs a patient registry and produces patient information with the help of an expert medical advisory team. Membership of AMEND is free and open to patients and health professionals. AMEND continually strives to look for ways of improving the care and management of MEN patients. Multiple endocrine neoplasia (MEN) type 1 is a rare genetic disorder in which benign (noncancerous) tumors arise from the cells of various glands of the endocrine system, most often the parathyroid, pancreas and pituitary glands. These affected glands secrete excessive amounts of hormones into the bloodstream, which can result in a variety of symptoms. Some benign tumors associated with MEN type 1 can become malignant (cancerous). Multiple endocrine neoplasia type 2 (MEN type 2) is a rare genetic disorder characterized by tissue overgrowth or tumor formation in various endocrine glands including the thyroid, the adrenal glands and the parathyroid. MEN type 2 is further classified into three distinct subtypes, MEN type 2A, MEN type 2B and familial medullary thyroid cancer (FMTC). All three subtypes of MEN type 2 carry an increased risk of developing a specific form of thyroid cancer called medullary carcinoma. Individuals with MEN type 2A also have an increased risk of developing benign tumors of the parathyroid (adenomas) and the adrenal glands (pheochromocytomas). MEN type 2A is associated with pheochromocytomas, multiple tumors of nerve tissue (neuromas), and multiple nerve cell tumors (ganglioneuromatosis) in the gastrointestinal tract.

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.